IN8bio to Present at Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference
Provided By GlobeNewswire
Last update: Dec 2, 2024
NEW YORK, Dec. 02, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and co-founder, will present at NobleCon20 - Noble Capital Markets' Twentieth Annual Emerging Growth Equity Conference on Tuesday, December 3, 2024 at 10:30 am ET.
Read more at globenewswire.com
